ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 606

Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry

Berrin Zengin1, Nevsun Inanc2, Servet Akar3, Gerçek Can1, Ediz Dalkiliç4, Abdurrahman Tufan5, Soner Senel6, Suleyman Serdar Koca7, Handan Yarkan1, Yavuz Pehlivan8, Zeynep Erturk9, Berna Goker5, Haner Direskeneli2, Merih Birlik1, Nurullah Akkoc10 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 2Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 3Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, 4Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 5Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, 6Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, 7Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 8Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, 9Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, 10Rheumatology, İzmir, Turkey, İzmir, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: registry, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was to investigate the drug survival, its efficacy and safety in patients with RA based on the database from the Turkish TURKBIO registry.

Methods:

A total of 180 patients (152 female, median age: 54.5 years) were treated with tofacitinib for RA. Drug survival was assessed. In 118 patients with available data, treatment response was evaluated using the number of sensitive and swollen joints, VAS values, DAS28, HAQ scores and CRP levels at weeks 12, 24, 48 and 60.

Results:

At baseline, RA patients had a median (Q1-Q3) disease duration of 14 (8-19) years. 75 patients (42%) had used ≥1 biologics previously. The other demographic and clinical features of the patients were shown in Table 1. Median (Q1-Q3) follow-up period was 137 weeks. After 48 and 137 weeks, 75% and 48% of the patients respectively, maintened tofacitinib (Figure 1). The most common reason for drug discontinuation was ineffectiveness of treatment (63%), followed by adverse events (23%). After 12 weeks, all disease activity parameters were reduced significantly compared to the baseline and most of them continued to be reduced until week 60. No difference was observed in disease activity parameters between the groups with and without previous ≥1 biologics at weeks 0, 12 and 24 (Table 2). Remission rate was (43%) at week 60 (observed data), (Table 2).

A total of 9 adverse events (4 infection, 3 allergic reaction, 2 rash) were observed during the follow-up period.

Conclusion:

The results of this long-term observational study suggest that tofacitinib might be an effective and safe treatment option in RA patients. Treatment with this drug may provide good response rates in RA patients refractory previous biologicals.


Disclosure: B. Zengin, None; N. Inanc, None; S. Akar, None; G. Can, None; E. Dalkiliç, None; A. Tufan, None; S. Senel, None; S. S. Koca, None; H. Yarkan, None; Y. Pehlivan, None; Z. Erturk, None; B. Goker, None; H. Direskeneli, None; M. Birlik, None; N. Akkoc, None; F. Onen, None.

To cite this abstract in AMA style:

Zengin B, Inanc N, Akar S, Can G, Dalkiliç E, Tufan A, Senel S, Koca SS, Yarkan H, Pehlivan Y, Erturk Z, Goker B, Direskeneli H, Birlik M, Akkoc N, Onen F. Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/similiar-efficacy-of-tofacinitib-on-disease-activity-in-rheumatoid-arthritis-patients-with-and-without-previous-biologicals-results-from-the-turkbio-registry/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/similiar-efficacy-of-tofacinitib-on-disease-activity-in-rheumatoid-arthritis-patients-with-and-without-previous-biologicals-results-from-the-turkbio-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences